Molecular Diagnostic for Infectious Diseases Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type (Point-of-Care Testing and Laboratory Testing), End User [Point-of-Care Testing (Human Testing and Vet Testing) and Laboratory Testing (Human Testing and Vet Testing)], Application [Point-of-Care Testing (Detection of Single Pathogen, Detection of Two or More Pathogens, Evaluation of Emerging Novel Infections, Surveillance and Early Detection of Biothreat Agents and Diseases-Related Biomarker, and Antimicrobial Resistance Profiling) and Laboratory Testing (Patient stratification, Drug Regimen Selection, Toxicity Avoidance, Therapeutic Monitoring, and Detection of Predisposition to Disease)], Disease Type [Point-of-Care Testing (Sepsis, Prosthetic Joint Infection, Endocarditis, STDs, Mononucleosis, Group A Streptococcus, and Others) and Laboratory Testing (Sepsis, Prosthetic Joint infection, Endocarditis, STDs, Chlamydia, Gastrointestinal Infection, Tuberculosis, H1N1 Virus, and Others)], Infection Type [Point-of-Care Testing (Bacteria, Viral, Fungi, and Others) and Laboratory Testing (Bacteria, Viral, Fungi, and Others)], and Geography (North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa)
The molecular diagnostic for infectious diseases market size is expected to reach US$ 17.614 billion by 2030 from US$ 6.833 billion in 2022; it is estimated to record a CAGR of 12.5% from 2022 to 2030.
The growing demand for better treatment modalities has resulted in various product developments in the last few decades. A few of the examples of recent product developments in the molecular diagnostic for infectious diseases market are mentioned below.
Genetic and genomic research has led to the development of molecular diagnostic techniques that focus on nucleic acid detection, which provide new methods for detecting infectious diseases with a fast turnaround time. A molecular diagnostic technique detects multiple pathogens and analyzes drug-resistant genes of pathogens and pathogen homology analysis, making it an increasingly important tool for the early diagnosis of infectious diseases. Molecular diagnostic techniques and platforms are used in all areas of anatomic and clinical pathologies. DNA or RNA sequences associated with disease, including single nucleotide polymorphism, deletions, rearrangements, and insertions, can be detected via molecular diagnostic tests. Conventionally, CT scans, hematological tests, and reverse transcription-PCR (RT-PCR) were used for testing. Due to growing infectious diseases, the need for rapid, precise testing platforms surged to overcome the disadvantages of conventional testing. Computed tomography (CT), a cost-intensive procedure that may not be available in all hospitals, fails to detect viral infections and other diseases in asymptomatic patients. RT-PCR was also time-consuming and could not detect a low viral load during the early stages of infection. Reverse transcription loop-mediated isothermal amplification (RT-LAMP), microarray-based detection, aptamer-based diagnosis, SHERLOCK, SHERLOCKv2, FET Biosensors, cell-based potentiometric diagnosis, and molecular imprinting technology are a few examples of novel molecular diagnostics techniques developed for infectious disease diagnosis. In the last few years, the FDA reports have indicated that molecular testing, antigen-dependent testing, and serological testing have been approved due to the advancements. Collaborative efforts by scientific communities in different countries to manage infectious diseases and reduce the extent of mortality have benefited the overall molecular tools and diagnosis landscape, which will likely create significant opportunities for the molecular diagnostics for infectious diseases market in the future.
The molecular diagnostic for infectious diseases market is divided on the basis of type, disease type, infection type, application, and end user. Based on type, the market is classified into point-of-care testing and laboratory testing. The molecular diagnostic for infectious diseases market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The molecular diagnostic for infectious diseases market, by application, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of a single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarkers, and antimicrobial resistance profiling. Laboratory testing is further segmented into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The molecular diagnostic for infectious diseases market, by disease type, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of a sepsis, prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus (GAS), and others. Laboratory testing is further segmented into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The molecular diagnostic for infectious diseases market, by infection type, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Laboratory testing is further segmented into bacteria, viral, fungi, and others.
Based on geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the molecular diagnostic for infectious diseases market. The increasing acceptance of technologically advanced products, a rise in research and development activities, the presence of large healthcare businesses, and the growing use of molecular diagnostics kits for infectious disease diagnosis are among the key factors propelling the growth of the molecular diagnostics for infectious diseases market in North America. The molecular diagnostics for infectious diseases market growth in the US is primarily driven by the increasing prevalence of infectious disease, rising geriatric population, and multiple product launches by key players.
The National Institute of Health (NIH), Centers for Disease Control and Prevention (CDC), European Union, and United Nations International Children's Emergency Fund (UNICEF) are a few key primary and secondary sources referred to while preparing the report on the molecular diagnostic for infectious diseases market.
The growing demand for better treatment modalities has resulted in various product developments in the last few decades. A few of the examples of recent product developments in the molecular diagnostic for infectious diseases market are mentioned below.
- In April 2023, Bruker Introduced New Mycobacteria and Fungi IVD Solutions for MALDI Biotyper, and a Novel LiquidArray Gastrointestinal Syndromic Panel. With the introduction of new IVD workflows, kits, software and reference libraries for mycobacteria and fungi, the company further expand the applications of established MALDI Biotyper platform. This creates additional value for all current and future customers. The new LiquidArray Gastrointestinal is a next-generation syndromic panel with amazing pathogen coverage. It is ideal for laboratories which are interested in a broad screening approach to detect most pathogens in one run.
- In February 2023, Thermo Fisher Scientific launched PCR kits for infectious disease detection in India. Thermo Fisher Scientific announced that its Applied Biosystems TaqPath PCR kits for infectious diseases such as multi-drug-resistant tuberculosis (MTB MDR), M. tuberculosis complex (MTB), hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and for genetic analysis (HLA B27) have received licensing rights by the Central Drugs Standard Control Organisation (CDSCO) and will be manufactured in India in association with Mylab Discovery Solutions.
- In December 2021, Roche launched the first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark. The launch of the cobas omni Utility Channel enables laboratory professionals the flexibility of running CE-IVD assays, as well as designing their own laboratory developed tests (LDTs). This new offering expands access to critical and robust diagnostic tools that enables healthcare providers to deliver high quality care to patients worldwide, including access to regions with the highest disease burdens.
Genetic and genomic research has led to the development of molecular diagnostic techniques that focus on nucleic acid detection, which provide new methods for detecting infectious diseases with a fast turnaround time. A molecular diagnostic technique detects multiple pathogens and analyzes drug-resistant genes of pathogens and pathogen homology analysis, making it an increasingly important tool for the early diagnosis of infectious diseases. Molecular diagnostic techniques and platforms are used in all areas of anatomic and clinical pathologies. DNA or RNA sequences associated with disease, including single nucleotide polymorphism, deletions, rearrangements, and insertions, can be detected via molecular diagnostic tests. Conventionally, CT scans, hematological tests, and reverse transcription-PCR (RT-PCR) were used for testing. Due to growing infectious diseases, the need for rapid, precise testing platforms surged to overcome the disadvantages of conventional testing. Computed tomography (CT), a cost-intensive procedure that may not be available in all hospitals, fails to detect viral infections and other diseases in asymptomatic patients. RT-PCR was also time-consuming and could not detect a low viral load during the early stages of infection. Reverse transcription loop-mediated isothermal amplification (RT-LAMP), microarray-based detection, aptamer-based diagnosis, SHERLOCK, SHERLOCKv2, FET Biosensors, cell-based potentiometric diagnosis, and molecular imprinting technology are a few examples of novel molecular diagnostics techniques developed for infectious disease diagnosis. In the last few years, the FDA reports have indicated that molecular testing, antigen-dependent testing, and serological testing have been approved due to the advancements. Collaborative efforts by scientific communities in different countries to manage infectious diseases and reduce the extent of mortality have benefited the overall molecular tools and diagnosis landscape, which will likely create significant opportunities for the molecular diagnostics for infectious diseases market in the future.
The molecular diagnostic for infectious diseases market is divided on the basis of type, disease type, infection type, application, and end user. Based on type, the market is classified into point-of-care testing and laboratory testing. The molecular diagnostic for infectious diseases market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The molecular diagnostic for infectious diseases market, by application, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of a single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarkers, and antimicrobial resistance profiling. Laboratory testing is further segmented into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The molecular diagnostic for infectious diseases market, by disease type, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of a sepsis, prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus (GAS), and others. Laboratory testing is further segmented into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The molecular diagnostic for infectious diseases market, by infection type, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Laboratory testing is further segmented into bacteria, viral, fungi, and others.
Based on geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the molecular diagnostic for infectious diseases market. The increasing acceptance of technologically advanced products, a rise in research and development activities, the presence of large healthcare businesses, and the growing use of molecular diagnostics kits for infectious disease diagnosis are among the key factors propelling the growth of the molecular diagnostics for infectious diseases market in North America. The molecular diagnostics for infectious diseases market growth in the US is primarily driven by the increasing prevalence of infectious disease, rising geriatric population, and multiple product launches by key players.
The National Institute of Health (NIH), Centers for Disease Control and Prevention (CDC), European Union, and United Nations International Children's Emergency Fund (UNICEF) are a few key primary and secondary sources referred to while preparing the report on the molecular diagnostic for infectious diseases market.
1. INTRODUCTION
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Molecular Diagnostic for Infectious Diseases Market, by Geography (US$ Million)
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET - KEY INDUSTRY DYNAMICS
5.1 Market Drivers:
5.1.1 Surging Prevalence of Infectious Disease Globally
5.1.2 Rising Application of Molecular Diagnostics in Veterinary Infectious Diseases
5.2 Market Restraints
5.2.1 Limitations Associated with Molecular Testing
5.3 Market Opportunities
5.3.1 Advancements in Molecular Diagnostics Technologies
5.4 Future Trends
5.4.1 Molecular Diagnostics for Infectious Diseases in Personalized Medicine
5.5 Impact Analysis:
6. MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET - GLOBAL MARKET ANALYSIS
6.1 Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 – 2030
7. GLOBAL MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET – REVENUE AND FORECAST TO 2030 – BY TYPE
7.1 Overview
7.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
7.3 Point-of-Care Testing
7.3.1 Overview
7.3.2 Point-of-Care Testing: Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Laboratory Testing
7.4.1 Overview
7.4.2 Laboratory Testing: Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
8. GLOBAL MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET – REVENUE AND FORECAST TO 2030 – BY END USER
8.1 Overview
8.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by End User, 2022 & 2030 (%)
8.2.1 Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
8.2.2 Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
9. GLOBAL MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET – REVENUE AND FORECAST TO 2030 – BY APPLICATION
9.1 Overview
9.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
9.3 Point-of-Care Testing
9.3.1 Overview
9.3.2 Global: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
9.4 Laboratory Testing
9.4.1 Overview
9.4.2 Global: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
10. GLOBAL MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET – REVENUE AND FORECAST TO 2030 – BY DISEASE TYPE
10.1 Overview
10.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
10.3 Point-of-Care Testing
10.3.1 Overview
10.3.2 Global: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
10.3.2.1 Global: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
10.4 Laboratory Testing
10.4.1 Overview
10.4.2 Global: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
10.4.2.1 Global: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11. GLOBAL MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET – REVENUE AND FORECAST TO 2030 – BY INFECTION TYPE
11.1 Overview
11.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
11.3 Point-of-Care Testing
11.3.1 Overview
11.3.2 Global: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.4 Laboratory Testing
11.4.1 Overview
11.4.2 Global: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12. MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET - GEOGRAPHICAL ANALYSIS
12.1 North America Molecular Diagnostic for Infectious Diseases Market, Revenue and Forecast To 2030
12.1.1 Overview
12.1.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.1.3 North America: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.1.4 North America: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.1.5 North America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.1.6 North America: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.1.7 North America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.1.8 North America: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.1.8.1 North America: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.1.9 North America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.1.9.1 North America: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.1.10 North America: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.1.11 North America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.1.12 North America Molecular Diagnostic for Infectious Diseases Market, by Country
12.1.12.1 US
12.1.12.1.1 US Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.1.12.1.2 US: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.1.12.1.3 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.1.12.1.4 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.1.12.1.5 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.1.12.1.6 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.1.12.1.7 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.1.12.1.7.1 US: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.1.12.1.8 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.1.12.1.8.1 US: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.1.12.1.9 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.1.12.1.10 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.1.12.2 Canada
12.1.12.2.1 Canada Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.1.12.2.2 Canada: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.1.12.2.3 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.1.12.2.4 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.1.12.2.5 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.1.12.2.6 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.1.12.2.7 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.1.12.2.7.1 Canada: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.1.12.2.8 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.1.12.2.8.1 Canada: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.1.12.2.9 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.1.12.2.10 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.1.12.3 Mexico
12.1.12.3.1 Mexico Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.1.12.3.2 Mexico: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.1.12.3.3 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.1.12.3.4 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.1.12.3.5 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.1.12.3.6 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.1.12.3.7 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.1.12.3.7.1 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.1.12.3.8 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.1.12.3.8.1 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.1.12.3.9 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.1.12.3.10 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2 Europe Molecular Diagnostic for Infectious Diseases Market, Revenue and Forecast to 2030
12.2.1 Overview
12.2.2 Europe Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.3 Europe: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.4 Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.5 Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.6 Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.7 Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.8 Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.8.1 Europe: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.9 Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.9.1 Europe: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.10 Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.11 Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12 Europe Molecular Diagnostic for Infectious Diseases Market, by Country
12.2.12.1 UK
12.2.12.1.1 UK Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.1.2 UK: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.1.3 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.1.4 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.1.5 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.12.1.6 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.12.1.7 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.1.7.1 UK: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.12.1.8 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.1.8.1 UK: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.12.1.9 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.1.10 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.2 Germany
12.2.12.2.1 Germany Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.2.2 Germany: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.2.3 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.2.4 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.2.5 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.12.2.6 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.12.2.7 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.2.7.1 Germany: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.12.2.8 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.2.8.1 Germany: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.12.2.9 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.2.10 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.3 France
12.2.12.3.1 France Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.3.2 France: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.3.3 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.3.4 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.3.5 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.12.3.6 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.12.3.7 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.3.7.1 France: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.12.3.8 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.3.8.1 France: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.12.3.9 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.3.10 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.4 Italy
12.2.12.4.1 Italy Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.4.2 Italy: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.4.3 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.4.4 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.4.5 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.12.4.6 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.12.4.7 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.4.7.1 Italy: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.12.4.8 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.4.8.1 Italy: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.12.4.9 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.4.10 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.5 Spain
12.2.12.5.1 Spain Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.5.2 Spain: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.5.3 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.5.4 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.5.5 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.12.5.6 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.12.5.7 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.5.7.1 Spain: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.12.5.8 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.5.8.1 Spain: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.12.5.9 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.5.10 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.6 Austria
12.2.12.6.1 Austria Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.6.2 Austria: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.6.3 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.6.4 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.6.5 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.12.6.6 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.12.6.7 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.6.7.1 Austria: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.12.6.8 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.6.8.1 Austria: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.12.6.9 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.6.10 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.7 Belgium
12.2.12.7.1 Belgium Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.7.2 Belgium: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.7.3 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.7.4 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.7.5 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.12.7.6 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.12.7.7 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.7.7.1 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.12.7.8 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.7.8.1 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.12.7.9 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.7.10 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.8 Luxembourg
12.2.12.8.1 Luxembourg Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.8.2 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.8.3 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.8.4 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.8.5 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.12.8.6 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.12.8.7 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.8.7.1 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.12.8.8 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.8.8.1 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.12.8.9 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.8.10 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.9 The Netherlands
12.2.12.9.1 The Netherlands Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.9.2 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.9.3 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.9.4 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.9.5 The Netherlands: Molecular Diagnostic fo
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Molecular Diagnostic for Infectious Diseases Market, by Geography (US$ Million)
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET - KEY INDUSTRY DYNAMICS
5.1 Market Drivers:
5.1.1 Surging Prevalence of Infectious Disease Globally
5.1.2 Rising Application of Molecular Diagnostics in Veterinary Infectious Diseases
5.2 Market Restraints
5.2.1 Limitations Associated with Molecular Testing
5.3 Market Opportunities
5.3.1 Advancements in Molecular Diagnostics Technologies
5.4 Future Trends
5.4.1 Molecular Diagnostics for Infectious Diseases in Personalized Medicine
5.5 Impact Analysis:
6. MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET - GLOBAL MARKET ANALYSIS
6.1 Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 – 2030
7. GLOBAL MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET – REVENUE AND FORECAST TO 2030 – BY TYPE
7.1 Overview
7.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
7.3 Point-of-Care Testing
7.3.1 Overview
7.3.2 Point-of-Care Testing: Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Laboratory Testing
7.4.1 Overview
7.4.2 Laboratory Testing: Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
8. GLOBAL MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET – REVENUE AND FORECAST TO 2030 – BY END USER
8.1 Overview
8.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by End User, 2022 & 2030 (%)
8.2.1 Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
8.2.2 Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
9. GLOBAL MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET – REVENUE AND FORECAST TO 2030 – BY APPLICATION
9.1 Overview
9.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
9.3 Point-of-Care Testing
9.3.1 Overview
9.3.2 Global: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
9.4 Laboratory Testing
9.4.1 Overview
9.4.2 Global: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
10. GLOBAL MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET – REVENUE AND FORECAST TO 2030 – BY DISEASE TYPE
10.1 Overview
10.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
10.3 Point-of-Care Testing
10.3.1 Overview
10.3.2 Global: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
10.3.2.1 Global: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
10.4 Laboratory Testing
10.4.1 Overview
10.4.2 Global: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
10.4.2.1 Global: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11. GLOBAL MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET – REVENUE AND FORECAST TO 2030 – BY INFECTION TYPE
11.1 Overview
11.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
11.3 Point-of-Care Testing
11.3.1 Overview
11.3.2 Global: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.4 Laboratory Testing
11.4.1 Overview
11.4.2 Global: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12. MOLECULAR DIAGNOSTIC FOR INFECTIOUS DISEASES MARKET - GEOGRAPHICAL ANALYSIS
12.1 North America Molecular Diagnostic for Infectious Diseases Market, Revenue and Forecast To 2030
12.1.1 Overview
12.1.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.1.3 North America: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.1.4 North America: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.1.5 North America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.1.6 North America: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.1.7 North America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.1.8 North America: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.1.8.1 North America: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.1.9 North America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.1.9.1 North America: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.1.10 North America: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.1.11 North America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.1.12 North America Molecular Diagnostic for Infectious Diseases Market, by Country
12.1.12.1 US
12.1.12.1.1 US Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.1.12.1.2 US: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.1.12.1.3 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.1.12.1.4 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.1.12.1.5 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.1.12.1.6 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.1.12.1.7 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.1.12.1.7.1 US: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.1.12.1.8 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.1.12.1.8.1 US: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.1.12.1.9 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.1.12.1.10 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.1.12.2 Canada
12.1.12.2.1 Canada Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.1.12.2.2 Canada: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.1.12.2.3 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.1.12.2.4 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.1.12.2.5 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.1.12.2.6 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.1.12.2.7 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.1.12.2.7.1 Canada: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.1.12.2.8 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.1.12.2.8.1 Canada: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.1.12.2.9 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.1.12.2.10 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.1.12.3 Mexico
12.1.12.3.1 Mexico Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.1.12.3.2 Mexico: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.1.12.3.3 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.1.12.3.4 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.1.12.3.5 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.1.12.3.6 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.1.12.3.7 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.1.12.3.7.1 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.1.12.3.8 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.1.12.3.8.1 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.1.12.3.9 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.1.12.3.10 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2 Europe Molecular Diagnostic for Infectious Diseases Market, Revenue and Forecast to 2030
12.2.1 Overview
12.2.2 Europe Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.3 Europe: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.4 Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.5 Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.6 Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.7 Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.8 Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.8.1 Europe: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.9 Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.9.1 Europe: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.10 Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.11 Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12 Europe Molecular Diagnostic for Infectious Diseases Market, by Country
12.2.12.1 UK
12.2.12.1.1 UK Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.1.2 UK: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.1.3 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.1.4 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.1.5 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.12.1.6 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.12.1.7 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.1.7.1 UK: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.12.1.8 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.1.8.1 UK: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.12.1.9 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.1.10 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.2 Germany
12.2.12.2.1 Germany Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.2.2 Germany: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.2.3 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.2.4 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.2.5 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.12.2.6 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.12.2.7 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.2.7.1 Germany: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.12.2.8 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.2.8.1 Germany: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.12.2.9 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.2.10 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.3 France
12.2.12.3.1 France Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.3.2 France: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.3.3 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.3.4 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.3.5 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.12.3.6 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.12.3.7 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.3.7.1 France: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.12.3.8 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.3.8.1 France: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.12.3.9 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.3.10 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.4 Italy
12.2.12.4.1 Italy Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.4.2 Italy: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.4.3 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.4.4 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.4.5 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.12.4.6 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.12.4.7 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.4.7.1 Italy: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.12.4.8 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.4.8.1 Italy: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.12.4.9 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.4.10 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.5 Spain
12.2.12.5.1 Spain Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.5.2 Spain: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.5.3 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.5.4 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.5.5 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.12.5.6 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.12.5.7 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.5.7.1 Spain: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.12.5.8 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.5.8.1 Spain: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.12.5.9 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.5.10 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.6 Austria
12.2.12.6.1 Austria Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.6.2 Austria: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.6.3 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.6.4 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.6.5 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.12.6.6 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.12.6.7 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.6.7.1 Austria: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.12.6.8 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.6.8.1 Austria: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.12.6.9 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.6.10 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.7 Belgium
12.2.12.7.1 Belgium Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.7.2 Belgium: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.7.3 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.7.4 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.7.5 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.12.7.6 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.12.7.7 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.7.7.1 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.12.7.8 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.7.8.1 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.12.7.9 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.7.10 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.8 Luxembourg
12.2.12.8.1 Luxembourg Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.8.2 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.8.3 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.8.4 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.8.5 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
12.2.12.8.6 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
12.2.12.8.7 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.8.7.1 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
12.2.12.8.8 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
12.2.12.8.8.1 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
12.2.12.8.9 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.8.10 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12.2.12.9 The Netherlands
12.2.12.9.1 The Netherlands Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
12.2.12.9.2 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
12.2.12.9.3 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
12.2.12.9.4 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
12.2.12.9.5 The Netherlands: Molecular Diagnostic fo
